Krampera M. Mesenchymal stromal cell ‘licensing’: a multistep process. Leukemia. 2011;25:1408–14. https://doi.org/10.1038/leu.2011.108.

Article  CAS  PubMed  Google Scholar 

Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One. 2010;5:e10088. https://doi.org/10.1371/journal.pone.0010088.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kota DJ, DiCarlo B, Hetz RA, Smith P, Cox CS Jr, Olson SD. Differential MSC activation leads to distinct mononuclear leukocyte binding mechanisms. Sci Rep. 2014;4:4565. https://doi.org/10.1038/srep04565.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells. 2008;26:99–107. https://doi.org/10.1634/stemcells.2007-0563.

Article  CAS  PubMed  Google Scholar 

Liotta F, Angeli R, Cosmi L, Filì L, Manuelli C, Frosali F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells. 2008;26:279–89. https://doi.org/10.1634/stemcells.2007-0454.

Article  CAS  PubMed  Google Scholar 

Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 2009;27:909–19. https://doi.org/10.1002/stem.7.

Article  CAS  PubMed  Google Scholar 

Kurte M, Vega-Letter AM, Luz-Crawford P, Djouad F, Noël D, Khoury M, et al. Time-dependent LPS exposure commands MSC immunoplasticity through TLR4 activation leading to opposite therapeutic outcome in EAE. Stem Cell Res Ther. 2020;11:416. https://doi.org/10.1186/s13287-020-01840-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rashedi I, Gómez-Aristizábal A, Wang XH, Viswanathan S, Keating A. TLR3 or TLR4 activation enhances mesenchymal stromal cell-mediated Treg induction via Notch signaling. Stem Cells. 2017;35:265–75. https://doi.org/10.1002/stem.2485.

Article  CAS  PubMed  Google Scholar 

Qiu Y, Guo J, Mao R, Chao K, Chen BL, He Y, et al. TLR3 preconditioning enhances the therapeutic efficacy of umbilical cord mesenchymal stem cells in TNBS-induced colitis via the TLR3-Jagged-1-Notch-1 pathway. Mucosal Immunol. 2017;10:727–42. https://doi.org/10.1038/mi.2016.78.

Article  CAS  PubMed  Google Scholar 

Park A, Park H, Yoon J, Kang D, Kang MH, Park YY, et al. Priming with Toll-like receptor 3 agonist or interferon-gamma enhances the therapeutic effects of human mesenchymal stem cells in a murine model of atopic dermatitis. Stem Cell Res Ther. 2019;10:66. https://doi.org/10.1186/s13287-019-1164-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15:42–49. https://doi.org/10.1038/nm.1905.

Article  CAS  PubMed  Google Scholar 

Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386–98. https://doi.org/10.1634/stemcells.2005-0008.

Article  CAS  PubMed  Google Scholar 

English K, Barry FP, Field-Corbett CP, Mahon BP. IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett. 2007;110:91–100. https://doi.org/10.1016/j.imlet.2007.04.001.

Article  CAS  PubMed  Google Scholar 

Ren G, Su J, Zhang L, Zhao X, Ling W, L'huillie A, et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009;27:1954–62. https://doi.org/10.1002/stem.118.

Article  CAS  PubMed  Google Scholar 

Tobin LM, Healy ME, English K, Mahon BP. Human mesenchymal stem cells suppress donor CD4(+) T cell proliferation and reduce pathology in a humanized mouse model of acute graft-versus-host disease. Clin Exp Immunol. 2013;172:333–48. https://doi.org/10.1111/cei.12056.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38:1745–55. https://doi.org/10.1002/eji.200738129.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murphy N, Treacy O, Lynch K, Morcos M, Lohan P, Howard L, et al. TNF-α/IL-1β—licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung. FASEB J. 2019;33:9404–21. https://doi.org/10.1096/fj.201900047R.

Article  CAS  PubMed  Google Scholar 

Duijvestein M, Wildenberg ME, Welling MM, Hennink S, Molendijk I, van Zuylen VL, et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells. 2011;29:1549–58. https://doi.org/10.1002/stem.698.

Article  CAS  PubMed  Google Scholar 

Kim DS, Jang IK, Lee MW, Ko YJ, Lee DH, Lee JW, et al. Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-gamma. EBioMedicine. 2018;28:261–73. https://doi.org/10.1016/j.ebiom.2018.01.002.

Article  PubMed  PubMed Central  Google Scholar 

Boland L, Burand AJ, Brown AJ, Boyt D, Lira VA, Ankrum JA. IFN-γ and TNF-α pre-licensing protects mesenchymal stromal cells from the pro-inflammatory effects of palmitate. Mol Ther. 2018;26:860–73. https://doi.org/10.1016/j.ymthe.2017.12.013.

Article  CAS  PubMed  Google Scholar 

Fan H, Zhao G, Liu L, Liu F, Gong W, Liu X, et al. Pre-treatment with IL-1beta enhances the efficacy of MSC transplantation in DSS-induced colitis. Cell Mol Immunol. 2012;9:473–81. https://doi.org/10.1038/cmi.2012.40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu H, Zhu X, Cao X, Chi A, Dai J, Wang Z, et al. IL-1beta-primed mesenchymal stromal cells exert enhanced therapeutic effects to alleviate Chronic Prostatitis/Chronic Pelvic Pain Syndrome through systemic immunity. Stem Cell Res Ther. 2021;12:514. https://doi.org/10.1186/s13287-021-02579-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noronha NC, Mizukami A, Caliári-Oliveira C, Cominal JG, Rocha J, Covas DT, et al. Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies. Stem Cell Res Ther. 2019;10:131. https://doi.org/10.1186/s13287-019-1224-y.

Article  PubMed  Google Scholar 

Liu F, Qiu H, Xue M, Zhang S, Zhang X, Xu J, et al. MSC-secreted TGF-beta regulates lipopolysaccharide-stimulated macrophage M2-like polarization via the Akt/FoxO1 pathway. Stem Cell Res Ther. 2019;10:345. https://doi.org/10.1186/s13287-019-1447-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu F, Xie J, Zhang X, Wu Z, Zhang S, Xue M, et al. Overexpressing TGF-beta1 in mesenchymal stem cells attenuates organ dysfunction during CLP-induced septic mice by reducing macrophage-driven inflammation. Stem Cell Res Ther. 2020;11:378. https://doi.org/10.1186/s13287-020-01894-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Melief SM, Schrama E, Brugman MH, Tiemessen MM, Hoogduijn MJ, Fibbe WE, et al. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. Stem Cells. 2013;31:1980–91. https://doi.org/10.1002/stem.1432.

Article  CAS  PubMed  Google Scholar 

Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2017;14:423–31. https://doi.org/10.1038/cmi.2015.89.

Article  CAS  PubMed  Google Scholar 

Yang R, Gao H, Chen L, Fang N, Chen H, Song G, et al. Effect of peripheral blood-derived mesenchymal stem cells on macrophage polarization and Th17/Treg balance in vitro. Regen Ther. 2020;14:275–83. https://doi.org/10.1016/j.reth.2020.03.008.

Article  PubMed  PubMed Central  Google Scholar 

Luz-Crawford P, Kurte M, Bravo-Alegría J, Contreras R, Nova-Lamperti E, Tejedor G, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Res Ther. 2013;4:65. https://doi.org/10.1186/scrt216.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmidt A, Zhang XM, Joshi RN, Iqbal S, Wahlund C, Gabrielsson S, et al. Human macrophages induce CD4(+)Foxp3(+) regulatory T cells via binding and re-release of TGF-beta. Immunol Cell Biol. 2016;94:747–62. https://doi.org/10.1038/icb.2016.34.

Article  CAS  PubMed  Google Scholar 

Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG, et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA. 2010;107:5652–7. https://doi.org/10.1073/pnas.0910720107.

Article  PubMed  PubMed Central  Google Scholar 

Kavanagh H, Mahon BP. Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy. 2011;66:523–31. https://doi.org/10.1111/j.1398-9995.2010.02509.x.

Article  CAS  PubMed